title: Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression.
abstract: The transcription factor E2F-1, a downstream regulator of the p16-cyclinD-Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of E2F-1 can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of E2F-1 expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze E2F-1 expression in ESCC, we investigated the immunoreactivity of E2F-1 and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive E2F-1 immunostaining was detected in 73 patients (59.8%). Positive E2F-1 immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with E2F-1-positive tumors than in patients with E2F-1-negative tumors (P = 0.0290). Over-expression of E2F-1 is associated with tumor progression and a worse prognosis after surgery in ESCC.
authors.affiliation: Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. yuma-ebi@wc4.so-net.ne.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Ebihara
authors.forename: M
authors.initials: M
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Shichinohe
authors.forename: Y
authors.initials: Y
authors.lastname: Kawarada
authors.forename: Y
authors.initials: Y
authors.lastname: Cho
authors.forename: A
authors.initials: A
authors.lastname: Fukunaga
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: H
authors.initials: H
authors.lastname: Uehara
authors.forename: H
authors.initials: H
authors.lastname: Kaneko
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: S
authors.initials: S
authors.lastname: Okushiba
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: H
authors.initials: H
authors.lastname: Katoh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D018797:Cell Cycle Proteins / Q000096:biosynthesis* / Q000235:genetics; D016009:Chi-Square Distribution; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics; D015536:Down-Regulation; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; D004938:Esophageal Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D016629:Esophagectomy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014157:Transcription Factors / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D014157:Transcription Factors